Dr.rer.nat. Solveigh Cornelia Koeberle
+43 316 380 - 5532
Institute of Pharmaceutical Sciences / Pharmacognosy
University of Graz
Beethovenstraße 8, A-8010 Graz, Austria
Room: 0111-03-0090
https://pharmazie.uni-graz.at/en/research/pharmacognosy/dr.-rer.-nat.-dipl.-pharm.-solveigh-koeberle
Dr. Solveigh Koeberle studied pharmacy and obtained her doctorate in medicinal chemistry at the University of Tübingen. After a two-year post-doctoral fellowship at the University of Tokyo (Cellular Neurobiology) and research stays at the Leibniz Institute on Aging (FLI Jena) and the University of Jena, she worked as Senior Lecturer in Pharmacognosy and Principal Investigator at the Michael Popp Institute in Innsbruck. From 2022 to 2024, she held an interim professorship in medicinal chemistry at the University of Regensburg. Her research, funded by the renowned Elise Richter Program of the Austrian Science Fund (FWF), focuses on the development of innovative drug candidates, the elucidation of molecular targets and disease mechanisms, and the exploration of novel therapeutic approaches for degenerative diseases such as metabolic-associated fatty liver disease (MAFLD), Alzheimer's and Parkinson's, with a particular focus on ferroptosis-inhibiting natural products.
ORCID: 0000-0002-8008-494X
Find an up-to-date list of Solveigh’s publications on PubMed
2025-2029: Member of the COST Action CA24138 - EU-Resolution Biology Network (EU-RESOLVE)
2025-2029: Member of the Management Committee of the COST Action CA24138 - EU-Resolution Biology Network (EU-RESOLVE)
2025-2029: Elise Richter Excellence Fellow (Grant DOI 10.55776/RIC4054324)
2025-2029: Elise Richter Excellence Fellow (Grant DOI 10.55776/RIC4054324)
2019-2021: Grant of the Friedrich Schiller University Jena (Germany)
2016-2017: Fellowship of the Leibniz Institute on Aging Jena (Germany)
2014-2015: Fellowship of the Leibniz Institute on Aging Jena (Germany)
2009-2011: Fellowship of the „Deutsche Pharmazeutische Gesellschaft“(DPhG) / Pharmaceutical Society of Japan (PSJ) and of the Takeda Science Foundation for a 2-year research period at The University of Tokyo (Japan)
2005: Participation at the “55th meeting of Nobel laureates in Medicine, Chemistry, and Physics in Lindau” (Germany)
Since 2025: Member of the Society for Redox Biology and Medicine (SfRBM)
Since 2024: Member of the Österreichische Pharmazeutische Gesellschaft (OePHG)
Since 2024: Member of the Society for Medicinal Plant and Natural Product Research (GA)
Since 2024: Board Member of the HMPPA
Since 2020: Member of the Herbal Medicinal Products Platform Austria (HMPPA)
Since 2018: Member of the Society of Minerals and Trace Elements (GMS)
2010: Member of the “Japanese Society of Neuroscience”
Since 2009: Member of the Takeda Science Foundation
Since 2004: Member of the German Pharmaceutical Society (DPhG)
Koeberle, S. (2025) The role of biogenic agents for protection of hepatic burden, INVITED TALK at the KIMCL Graz Advanced Training Series, Medical University of Graz (Graz, Austria)
Koeberle, S. (2025) Redox-regenerative natural products: An innovative approach to ferroptosis inhibition and redox balance maintenance, Society for Medicinal Plant and Natural Product Research (GA) Annual Meeting (Naples, Italy)
Koeberle, S. (2025) Biogenic inhibitors as gateways to druggable mechanisms in ferroptosis protection, INVITED TALK, Good Practice Traditional Chinese Medicine (GP-TCM) RA Annual Meeting (London, UK)
Koeberle, S. (2025) Decoding Ferroptosis: Natural product inspired drug discovery in degenerative disease, Meeting of the European Federation of Pharmaceutical Science (EUFEPS) (Vienna, Austria)
Koeberle, S. (2024) Uncovering redox-regenerating agents to combat ferroptosis INVITED TALK (University of MCLouvain (UCL), Brussels, Belgium).
Koeberle, S. (2024) Uncovering redox-regenerating agents to combat ferroptosis, INVITED TALK at the Lecture Series Cancer Biology (Ludwig-Maximilians-Universität München, München, Germany).
Koeberle, S. (2024) Utilizing FSP1 Oxidoreductase for Efficient Redox Regeneration of Radical Scavengers in Ferroptosis Protection, INVITED TALK at the Lecutures Series of the PhD Student/PostDoc Seminar of the SPP2306 Priority Program “Ferroptosis: from Molecular Basics to Clinical Applications”.
Koeberle, S. (2024) Utilizing FSP1 Oxidoreductase for Efficient Redox Regeneration of Radical Scavengers in Ferroptosis Protection, Austrian Summit on Natural Products (Seefeld, Austria).
Koeberle, S. (2023) Hijacking endogenous redox cycles to mitigate ferroptoticcell death, Annual Meeting of the German Pharmaceutical Society (DPhG) (Tübingen, Germany).
Koeberle, S. (2023) Manipulating endogenous redox systems to protect against ferroptotic cell death, Oral presentation at the Seminar "Current Discoveries in Biomedical Research" (Innsbruck, Austria).
Koeberle, S. (2023) Targeting lipid metabolism at the crossroad of different cell death programs, EMBO Workshop Ferroptosis: When metabolism meets cell death (Seeon- Seebruck, Germany).
Koeberle, S. (2022) To live or to die: Reprogramming cell fate with natural products, Meeting of the Center for Molecular Biosciences Innsbruck (CMBI) (Igls, Austria).
Koeberle, S. (2022) NRF2 cysteine code in ferroptosis and necroinflammation, INVITED TALK, Mini-Symposium: Michael Popp Institute, University of Innsbruck - German Cancer Research Center, Heidelberg. Cell death: metabolism, bioactive lipids and therapeutic strategies, VIRTUAL.
Koeberle, S. (2022) Selenium in NRF2 dependent redox signaling, INVITED TALK, International Conference of Trace Elements and Minerals (ICTEM) (Aachen, Germany).
Koeberle, S. (2021) Structural requirements of silybin from Silybum marianum that favourably shift fatty acids from triglycerides towards phospholipids in liver, INVITED TALK, HMPPA Symposium Milk Thistle: Phytochemical, pharmacological and clinical evidence, VIRTUAL.
Koeberle, S. (2021) Biogenic ferroptosis-modulating compounds: Challenges and opportunities in interfering with redox signalling and potential therapeutic applications, HMPPA Symposium “Next Generation in Pharmacognosy (Krems, Austria).
Koeberle, S. (2021) Redox-dependent regulation of inflammatory lipid mediator biosynthesis by glutathione peroxidases 1 and 2 as promising novel anti-inflammatory strategy, Highlight Talk, Annual Meeting of the German Pharmaceutical Society (DPhG), VIRTUAL.
Koeberle, S. (2021) The flavonolignan silybin from Silybum marianum targets hepatic lipid biosynthesis and elevates the hepatic biotransformation capacity, Society for Medicinal Plant and Natural Product Research (GA) Annual Meeting, VIDEO CONTRIBUTION.
Koeberle, S. (2021) Glutathione peroxidases 1 and 2 as promising targets in anti-inflammatory therapy, Highlight Talk, Meeting of the European Federation of Pharmaceutical Science (EUFEPS), VIRTUAL.
Koeberle, S. (2021) Glutathione peroxidases – Novel targets of anti-inflammatory drugs? Highlight Talk, Frontiers in Medicinal Chemistry, VIRTUAL.
Koeberle, S. (2021) Impact of the trace element selenium on macrophages during differentiation, Scientific Congress of the German Society of Nutrition (DGE), VIRTUAL.
Koeberle, S. (2020) Selenoproteins in redox-dependent inflammatory signaling, Seminar series “Current research results in Pharmacy“ (University of Innsbruck, VIRTUAL).
Koeberle, S. (2012) Forgotten neuronal signaling mechanisms: Importance of contact-dependent processes in brain development, Leibniz Institute on Aging (Jena, Germany).
Koeberle, S. (2011) What is the role of the tumor suppressor gene NF2 in the brain during development? Leibniz Institute on Aging Evaluation (Jena, Germany).
Koeberle, S. (2011) Role of CaMKIIα activity in spine formation and morphology during development, INVITED TALK, Leibniz Institute on Aging (Jena, Germany).
Koeberle, S. (2010) Role of CaMKIIα activity in spine formation and dendritic arborisation during development, Joint Workshop, University of Tokyo, (Tokyo, Japan).
Koeberle, S. (2009) Synthese und biologische Testung neuer aza-analoger und disubstituierter Dibenzepinone als Hemmstoffe der p38 MAP, University of Tübingen (Tübingen, Germany).
Koeberle, S. (2005) Synthese von Dibenzosuberonderivaten als allosterische p38 MAP Kinase Inhibitoren, University of Tübingen (Tübingen, Germany).
2025: Honored as ‘Styrian of the Day’ in “Kleine Tageszeitung following publication on milk thistle (https://www.kleinezeitung.at/steiermark/steirerdestages/19302820/sie-sagt-der-fettleber-mit-ihrer-forschung-den-kampf-an)
2025: Article in the health magazine Botenstoff on milk thistle research: Koeberle et al., Theranostics 2025 (https://www.humantechnology.at/wp-content/uploads/2025/03/Botenstoff-Maerz-2025-1.pdf)
2025: Press release Ran ans Fett: Forscher:innen entschlüsseln Stoff aus Mariendistel gegen Leber-Erkrankungen“ on the occasion of the publication Koeberle et al., Theranostics 2025 (https://www.uni-graz.at/de/neuigkeiten/ran-ans-fett/)
2024: University of Graz press release: Awarded funding for Elise-Richter Project (https://pharmazie.uni-graz.at/en/news/bewilligung-des-elise-richter-projekts/)
2022: Long Night of Research 2022 in Innsbruck Organization of the station: “Traditional medicinal plants and modern drug development - contradiction or successful coexistence?“
2021: Contribution to the reorganization of the sector “Medicinal Plants” and “Agricultural Plants” of the Botanical Garden in Innsbruck
- Nature (IF 54.4)
- Molecular Cancer (IF 31.3)
- Cancer Communcations (IF 16.7)
- Advanced Science (IF 16.3)
- Theranostics (IF 12.4)
- British Journal of Pharmacology (IF 8.7)
- Cell Chemical Biology (IF 7.2)
- International Journal of Molecular Science (IF 6.2)
- Food and Chemical Toxicology (IF 5.6)
- BioMed Research International (IF 3.4)